The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004-2014
- PMID: 28314560
- DOI: 10.1016/j.vaccine.2017.03.007
The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004-2014
Abstract
Background: Invasive meningococcal disease (IMD) is a major cause of bacterial meningitis and septicaemia although infection by some serogroups may be prevented through vaccination. We aimed to describe the epidemiology of IMD in EU/EEA countries during 2004-2014 to monitor serogroup- and age-specific trends, and compare country trends by the period of meningococcal C conjugate (MCC) vaccine introduction.
Methods: We analysed IMD surveillance data by age, gender, serogroup, country and outcome. We estimated the percentage change in annual notification rate (NR), using linear regression analysis of the log of the annual NR. We grouped countries by the year they introduced MCC vaccination into their routine immunisation programmes.
Results: The overall NR was 0.9/100 000 population, and decreased 6.6% (95%CI: -8.0%;-5.1%) annually. Infants had the highest NR (16.0/100 000), and there were decreasing trends in all age groups <50years. Serogroup B (SgB) caused 74% of all cases, and the majority of cases in all age groups. There were decreasing trends in SgB and serogroup C (SgC) and an increasing trend in serogroup Y. Countries that introduced MCC vaccination before, and between 2004 and 2014, had decreasing trends in NR of SgC, but not countries without routine MCC vaccination.
Conclusions: Our findings support evidence that routine MCC vaccination was the driving force behind the decreasing SgC trend. Vaccinating against SgB in the first year of life could help reduce the burden of IMD due to this serogroup. Changing serogroup-specific NR trends highlight the need for high-quality surveillance data to accurately assess the changing epidemiology of IMD, the effectiveness and impact of implemented vaccines, and the need for future vaccines.
Keywords: Epidemiology; Europe; Invasive meningococcal disease (IMD); Neisseria meningitidis; Serogroup; Surveillance.
Copyright © 2017. Published by Elsevier Ltd.
Similar articles
-
Changing epidemiology of Infant Meningococcal Disease after the introduction of meningococcal serogroup C vaccine in Italy, 2006-2014.Vaccine. 2015 Jul 17;33(31):3678-81. doi: 10.1016/j.vaccine.2015.06.032. Epub 2015 Jun 16. Vaccine. 2015. PMID: 26087297
-
Meningococcal C conjugate vaccine effectiveness before and during an outbreak of invasive meningococcal disease due to Neisseria meningitidis serogroup C/cc11, Tuscany, Italy.Vaccine. 2018 Jul 5;36(29):4222-4227. doi: 10.1016/j.vaccine.2018.06.002. Epub 2018 Jun 9. Vaccine. 2018. PMID: 29895504
-
Reduction in Neisseria meningitidis infection in Italy after Meningococcal C conjugate vaccine introduction: A time trend analysis of 1994-2012 series.Hum Vaccin Immunother. 2016;12(2):467-73. doi: 10.1080/21645515.2015.1078951. Hum Vaccin Immunother. 2016. PMID: 26308192 Free PMC article.
-
The Global Evolution of Meningococcal Epidemiology Following the Introduction of Meningococcal Vaccines.J Adolesc Health. 2016 Aug;59(2 Suppl):S3-S11. doi: 10.1016/j.jadohealth.2016.04.012. J Adolesc Health. 2016. PMID: 27449148 Review.
-
Prevention of meningococcal disease: current use of polysaccharide and conjugate vaccines.Clin Infect Dis. 2010 Mar 1;50 Suppl 2:S45-53. doi: 10.1086/648964. Clin Infect Dis. 2010. PMID: 20144016 Review.
Cited by
-
Immunogenicity of meningococcal polysaccharide ACWY vaccine in primary immunized or revaccinated adults.Clin Exp Immunol. 2018 Dec;194(3):361-370. doi: 10.1111/cei.13202. Epub 2018 Sep 20. Clin Exp Immunol. 2018. PMID: 30099753 Free PMC article.
-
Societal costs due to meningococcal disease: a national registry-based study.Clinicoecon Outcomes Res. 2018 Oct 2;10:563-572. doi: 10.2147/CEOR.S175835. eCollection 2018. Clinicoecon Outcomes Res. 2018. PMID: 30323634 Free PMC article.
-
Vaccines and Senior Travellers.Front Aging. 2021 Jul 9;2:677907. doi: 10.3389/fragi.2021.677907. eCollection 2021. Front Aging. 2021. PMID: 35822022 Free PMC article. Review.
-
Prevalence and Characteristics of Carriage of Neisseria meningitidis Among Young Israeli Adults.Open Forum Infect Dis. 2022 Sep 19;9(10):ofac482. doi: 10.1093/ofid/ofac482. eCollection 2022 Oct. Open Forum Infect Dis. 2022. PMID: 36225741 Free PMC article.
-
Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adults 56 years of age and older: a Phase II randomized study.Hum Vaccin Immunother. 2020 Jun 2;16(6):1299-1305. doi: 10.1080/21645515.2020.1733868. Epub 2020 Apr 1. Hum Vaccin Immunother. 2020. PMID: 32233961 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical